Device Authority partnership expands route into enterprise IoT security

Tern plc

Device Authority has strengthened its enterprise market positioning through a strategic partnership with Xalient, bringing its KeyScaler platform into a managed cybersecurity model focused on identity-led protection for IoT and OT environments.

Enterprises are continuing to expand connected device estates across operational settings, where unmanaged assets, long device lifecycles and fragmented security processes can increase exposure to cyber risk. As these environments become more complex, demand is shifting towards automated tools that can manage device identity, access and compliance at scale.

The partnership gives Xalient the ability to integrate Device Authority’s KeyScaler technology into its IoT security offering. This is intended to help enterprise customers protect connected devices across complex environments by automating key parts of the device identity lifecycle. These include secure onboarding, credential provisioning, certificate rotation, decommissioning and policy-driven access control.

The collaboration also reflects the growing importance of Zero Trust-aligned security models. Rather than relying on static perimeter defences, enterprises need ways to verify and manage users, devices, workloads and machine identities continuously. KeyScaler is designed for IoT and OT environments, where traditional IT security tools may not be sufficient and where automation can help reduce the burden on internal teams.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Search